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Abstract
Background: The immune responses to bacterial products through the pattern recognition
receptor (PRR) play a pivotal role in pathogenesis of Crohn's disease. A recent study described an
association between CD and some gene coding for bacterial receptor like NOD2/CARD15 gene
and TLR4. In this study, we sought to determine whether TLR4 gene was associated with Crohn's
disease (CD) among the Tunisian population and its correlation with clinical manifestation of the
disease.
Methods: 90 patients with CD and 80 healthy individuals are genotyped for the Asp299Gly and
Thr399Ile polymorphisms by restriction fragment length polymorphism analysis.
Results: The allele and genotype frequency of the TLR4 polymorphisms did not differ between
patients and controls. The genotype-phenotype correlation permitted to show that the Thr399Ile
polymorphism was associated with early onset disease.
Conclusion: this study reported the absence of association between CD and TLR4 gene in the
Tunisian population, but this gene could play a role in clinical expression of the disease.
Background
Inflammatory bowel disease (IBD) is a multifactorial
polygenic disease. Some genetic markers increase the risk
of ulcerative colitis (UC) or Crohn's disease (CD) while
others are associated with a particular phenotypic expres-
sion like disease location and/or behaviour [1,2].
In addition to genetic predisposition, various environ-
mental factors play a key role in the pathogenesis of IBD
such as enteric bacterial flora. In IBD, a disturbed host-
bacteria interaction with an aberrant mucosal immune
response has been observed [3,4]. This basic immunolog-
ical mechanism in IBD is demonstrated by the recently
described association within IBD and gene coding for
receptor of bacterial products. In 2001, several studies
associated CD with NOD2/CARD15 gene which coding
for cytosolic receptor of bacterial muramyl dipeptides [5-
7]. The three common variants of NOD2 gene (SNP8:
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Arg702Trp; SNP12: Gly908Arg; SNP13: Leu1007insC)
induce an impairment of bacterial recognition. They are
associated with dysregulation of NFκB pathway and
reduced α defensin release from paneth cells [8-10]. How-
ever, there are significant geographical differences in the
frequency of these alleles [11]. These are not found among
Japanese, Chinese, Australian and Tunisian population
[12-15]; they are also less frequent in North European
countries [16,17].
Toll-like receptors 4 (TLR4) is a transmembrane protein
which plays a key role in bacterial lipopolysaccharides
(LPS) recognition and in initiating innate immune
responses [18]. It is a receptor of bacterial LPS [19]. TLR4
deficient mice are defective in their response to LPS. TLR4
is up regulated in the intestinal epithelial cells in patients
with ulcerative colitis and Crohn's disease (CD) [20].
Recently, two missense polymorphisms Asp299Gly  and
Thr399Ile affecting the extracellular domains of TLR4 were
associated with LPS hyporesponsiveness [21-23] and an
association was reported between these polymorphisms
and IBD [24-26].
The aim of this study was to investigate about the presence
of Asp299Gly and Thr399Ile polymorphisms of the TLR4
gene among a Tunisian population with CD. We also
aimed to investigate about any correlation between these
polymorphisms and clinical phenotypes of CD.
Methods
• Subjects
The study included 90 patients with Crohn's disease, 30
patients with ulcerative colitis and 80 healthy control
groups. All of them were Caucasian and the control group
was matched with the patient group for sex and age.
The diagnosis of CD or UC was determined by standard
clinical, radiological, endoscopic and histological criteria
[27].
CD was classified according to the Vienna Classification
[28]. CD patients were composed of 47 males and 43
females. Mean age was 35 years. CD was ileocolitis in 40
patients, ileitis in 22 patients and colitis in 28 patients.
Mean of follow up is 90 month (24–117 month). We ana-
lysed disease behaviour at latest follow-up.
Informed consent was obtained verbally from each partic-
ipant and an ethical approval was obtained by ethical
committee of La Rabta Hospital.
• Classification of the CD clinical phenotypes
We also applied an arbitrary classification based on the
disease severity, need for surgery and need for immuno-
suppressive therapy.
The severity of CD is evaluated by the behaviour of the
disease (penetrating, stricturing or inflammatory) and the
installation of an acute severe colitis requiring intensive
medical therapy. Within the category of severe CD,
patients requiring immunosuppressive therapy or surgery
were categorized under the phenotype "need for surgery"
or "need for immunosuppressive".
Other phenotypic details such as disease location, age at
diagnosis and presence of extra intestinal manifestations,
were also recorded.
• PCR analysis of TLR4 alleles
Genomic DNA was extracted from peripheral blood leu-
kocytes. The two mutations of the TLR4 gene (Asp299Gly
and Thr399Ile) were performed using polymerase chain
reaction (PCR) and restriction fragment length polymor-
phism analysis (RFLP). To amplify the coding regions, we
used the following primers:
for TLR4 Asp299Gly F: (5'AGCATACTTAGACTACTACCT
CCATG3'), R: (5'GAGAGATTTGAGTTTCAATGTGGG3')
and for TLR4 Thr399Ile F: (5'GGTTGCTGTTCTCAAAGTG
ATTTTGGGAGAA3'), R: (5'GGAAATCCAGATGTTCTAGT
TGTTCTAAGCC3').
The PCR was carried out by 30 cycles of denaturing at
94°C for 1 min, annealing at 55°C (Asp299Gly) and at
53°C (Thr399Ile) for 1 min, and extension at 72°C for 1
min. PCR products were cleaved overnight with Nco I for
Asp299Gly polymorphism and HinfI for Thr399Ile poly-
morphism (Biolabs) at 37°C and electrophored on a
2,5% agarose gel. The fragment sizes for carriers of the
polymorphic allele decreased from 188 bp (wild type:
alleleA) to 168 bp (allele G) for the Asp299Gly polymor-
phism and from 124 bp (wild type: allele C) to 98 bp
(allele T) for the Thr399Ile polymorphism.
• Statistical analysis
Chi square test was used to compare the allele and geno-
type frequencies among disease and control groups. To
correlate phenotype genotype state, the T-student test was
used for quantitative parameters and Fischer test for qual-
itative parameters. The Kaplan-Meir with Log-Rank test
was used to compare the delay of surgery within the dif-
ferent groups. P values less than 0.05 were considered sig-
nificant.
Results
Genotype frequency and allele distribution of TLR4
Asp299Gly polymorphism are summarized in table 1. The
genotype GG was not found in both patients and control
groups. The frequencies of the 299Gly allele were respec-
tively, 7,5% and 6% in CD and healthy controls. No sig-BMC Gastroenterology 2009, 9:62 http://www.biomedcentral.com/1471-230X/9/62
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nificant difference was noticed in the Asp299Gly
polymorphism frequencies among CD patients and con-
trols.
TLR4 Thr399Ile genotype carrier frequencies are summa-
rized in table 2. None patients and control, were homozy-
gote for allele T. The allele T was more frequent in CD
patient than controls (7% and 4,5% respectively) but the
difference was not significant. The distribution of
Thr399Ile polymorphism was similar in UC group, CD
and controls.
The correlation study between Asp299Gly polymorphism
and phenotype of CD didn't either allow to associate TLR4
genotype with specific disease behaviour, or with the
severity of CD. Whereas, for Thr399Ile polymorphism, we
noted an earlier onset of disease in CD patients carrying
allele T (27 years ± 9 vs 36 years ± 10). This difference is
statistically significant (p = 0.01) (table 3).
Different analyses, based on the time between the diagno-
sis of the complication and the onset of the disease: stric-
turing or penetrating form, acute severe colitis, need for
surgery or immunosuppressive therapy, have been stud-
ied. No significant differences were noticed between these
parameters and genotype (Figure 1 and Figure 2).
The extraintestinal manifestations are observed in 20% of
patients but only three of them have TLR4 mutations.
We also evaluated the co-existence of TLR4 mutations and
those of NOD2 and HSP70-2 genes in CD patients (previ-
ous studies for the same patients) [12-29]. The number of
patients carrying a TLR4 mutations and one of NOD2
and/or HSP70-2 mutations, was 20 (19%) vs 17% in con-
trols subjects. Statistically, no difference was noticed
between patients and controls.
The co-existence of TLR4 mutations was associated with
prevalent complications of CD (73% vs 27% p = 0.06).
Three of CD patients were carrying simultaneously a pol-
ymorphic allele of the three tested genes. These patients
have a severe form of the disease.
Additionally, 76% of the CD patients were carrying one
mutation of TLR4 gene, in minimum, compared to 65%
in controls group (p = 0.09).
Discussion
Following the identification of the NOD2/CARD15 gene
in CD, the role of innate immune system in the pathogen-
esis of IBD has gained an increasing attention. Compared
to mutations in the cytosolic receptor NOD2/CARD15,
the TLR4 polymorphisms caused an impaired response to
LPS [30]. Cario and Podolsky showed that TLR4 was
strongly up-regulated in CD and UC [20], this may be
caused by an exaggerated host defence reaction of the
intestinal epithelium to endogenous luminal bacterial
flora [31].
The importance of TLR4 polymorphisms in CD is less
clear than NOD2/CARD15. In healthy Caucasians, the
reported frequencies of these polymorphisms ranges are
between 7% and 12% [32].
Franchimont et al. have reported a two-fold elevation in
allele frequency of TLR4 Asp299Gly  in CD Belgium
patients [26]. The Thr399Ile variant was associated with
UC in German study [24]. Japanese [30] and Hungarian
studies [33] failed to detect any individuals displaying the
mutant alleles in TLR4. There is also no difference in TLR4
allele frequency between IBD patients and controls in pre-
liminary results of the EC-IBD study group [17].
These finding comfort our results, since in our study,
about TLR4 polymorphisms, no significant differences in
the allele or genotype frequencies between the study
groups were noticed. The small size of our cohort may
contribute to these negative results.
The correlative study between TLR4 mutations and CD,
allowed us to show an early disease onset in the subgroup
of patients, carrying a Thr399Ile variant in our study (27
years ± 9 vs 36 years ± 10; p = 0.01).
Table 1: TLR4 Asp299Gly polymorphism: Genotype and allele 
frequencies (%) of in Crohn's disease (CD) patients and controls.
CD (n = 90) Controls (n = 80) P
Genotype
AA 86% (78) 89% (71) 0.6
AG 14% (12) 11% (9)
GG 0 0
Alleles
A 93% (168) 94% (151) 0.6
G 7% (12) 6% (9)
Table 2: TLR4 Thr399Ile polymorphism: Genotype and allele 
frequencies (%)in Crohn's disease (CD) patients and controls.
CD (n = 90) UC (n = 30) Controls (n = 80) P
Genotype 0.38
CC 86% (77) 93% (28) 90% (72)
CT 14% (13) 7% (2) 10% (8)
TT 0 0 0
Alleles
C 93% (167) 97% (58) 95% (152) 0.5
T 7% (13) 3% (2) 5% (8)BMC Gastroenterology 2009, 9:62 http://www.biomedcentral.com/1471-230X/9/62
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In literature, the presence of variant TLR4 allele was ten-
dency to be associated with an early disease onset in Hun-
garian study (p = 0.06); the earliest onset was observed in
carriers of both variant NOD2/CARD15 and TLR4 alleles
(23 years vs 30.2 years; p = 0.01)[33]. These results differ
from those of another study that doesn't establish any
association between TLR4 polymorphisms and the age of
the disease onset [34]. This discrepancy of results necessi-
ties more study with a large cohort.
Ouburg et al. [35] described an association between the
TLR4 polymorphisms and colonic localisation (43% vs
12%; p = 0.0017). This association could not be con-
firmed in our study.
The three candidate genes of CD: NOD2, HSP70-2 and
TLR4, studied in the Tunisian population, were not asso-
ciated with the disease among our population, contrarily
to European and American results [29,36-38].
The co-existence of TLR4, NOD2/CARD15, HSP70-2
mutated alleles is distributed similarly in CD and control
group. It seems that these genes don't increase the risk of
Table 3: TLR4 alleles and clinical characteristics of CD patients.
Asp299Gly Thr399Ile
G(%) A(%) T(%) C(%)
Sex
M9 4 3 9 , 5 4 1 , 5
F 7 41,5 5 44
Age (years) 30 ± 12 36 ± 12 27 ± 9 36 ± 10*
Location
Ileum 5 19 1 21
Ileocolic 6 37 6 37
Colon 3 28 7 27
Anoperineal manifestations 2 28 2 28
Penetrating and/or Stricturing form 11 47 9,5 50
Acute severe colitis 3 12 3,5 15
Need for immunosuppressive 8 31,4 7 36
*: p = 0.01
Comparison of the delay of surgery between allelic variants  of Asp299Gly polymorphism Figure 1
Comparison of the delay of surgery between allelic 
variants of Asp299Gly polymorphism.
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Comparison of the delay of surgery between allelic variants  of Thr399Ile polymorphism Figure 2
Comparison of the delay of surgery between allelic 
variants of Thr399Ile polymorphism.
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developing the disease, but they play probably a role in
phenotype determines, since more complications were
noticed within patients carrying two or more mutations
(p = 0.06).
Three patients were found to carry mutations in all three
genes. These patients had an earlier disease onset (19, 23
et 30 years), an ileocolitis location, a stricturing perforat-
ing form and anoperinal manifestations and then, a
severe form of the disease.
Analysing the SNP interaction will allow an understand-
ing of the phenotypic variation of the disease, but until
now the results in CD are controversial. In fact, some stud-
ies show that the coexistence of mutations of NOD2/
CARD15 and TLR4 genes, increase the risk of developing
CD [39-43] or, is associated with the phenotype of the dis-
ease, but these results were not confirmed.
Conclusion
In conclusion, our study is unable to detect an association
within the TLR4 gene and CD, but this gene could be
implicated in the phenotype of the disease, mainly with
early onset of disease. The co-existence of several allelic
variant of TLR4, NOD2/CARD15 and HSP70-2 genes may
be associated with severe form of the Crohn's disease
among the Tunisian population.
The association between NOD2/CARD15, HSP70-2 and
TLR4 mutations with CD varies from a population to
another; within the USA, European, Asiatic or the Tuni-
sian population. Further genetic studies should definitely
resolve the impact of these genes in susceptibility to CD,
depending on the ethnic background.
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